Print Page   |   Contact Us   |   Sign In   |   Join Today
News & Press: General

Eyes on Washington: Federal Health Care Grant Notification Service

Tuesday, May 5, 2015   (0 Comments)
Posted by: TCAA Staff
Share |

 

Eyes on Washington: Federal Health Care Grant Notification Service

 

Grant Opportunities for April 27, 2015 through May 1, 2015

 

Visit Holland & Knight online

    

New Federal Health Care Grant Opportunities Announced for:

·         Administration for Children and Families (ACF)

·         Food and Drug Administration (FDA)

·         Health Resources and Services Administration (HRSA)

·         Defense Advanced Research Projects Agency (DARPA)

·         US Army Medical Research Acquisition Activity (USAMRAA)

·         National Institutes of Health (NIH)

 

 

NON-NIH Funding Opportunity Announcements:

 

ACF: Secondary Analyses of Data on Early Care and Education

Funding Opportunity Number: HHS-2015-ACF-OPRE-YE-1009

Grants for Secondary Analyses of Data on Child Care and Early Education will provide funding to address key questions that will inform both policymakers and future research through analysis of existing data sets. Data of various types and from a number of sources may be mined for these purposes. Some examples of national datasets that are candidates for secondary analyses include, but are not limited to (1) the National Survey of Early Care and Education, (2) the Early Childhood Longitudinal Study, (3)  National Longitudinal Study of Youth, and (4) the Fragile Families and Child Well-Being Study. Secondary analyses may also consider national-level or state-level administrative and systems data and primary research and evaluation data. Topics of particular interest for these grants are: (1) measurement of quality; (2) access to high quality early care and education for their children; (3) qualifications, certification and credentialing of child care teachers and caregivers and its relationship to quality care and interactions between caregivers/teachers and children; (4) interplay between family and child characteristics, employment status, and choices of care; (5) child care characteristics and child and family outcomes; (6) implementation assessment (or process evaluation) of programs / initiatives; (7) effectiveness of state systems in monitoring and maintaining standards of care, and relationship between qualification of monitors/inspectors and the effectiveness of monitoring systems; (8) cost-benefit / cost-effectiveness analyses of child care initiatives; (9) collaboration, coordination, and alignment of services among early care and education programs; (10) characteristics of early care and education programs (center-based and home-based) and their relationship to indicators of program quality; and, (11) characteristics of early care and education (ECE) programs available to children from low-income households, of diverse race, ethnicity, and primary language, and of different ages. Grantees are required to produce at least one research-to-policy or practice brief based on the findings from the secondary analyses by the end of the project period to be disseminated broadly to policy and research audiences and present such findings at a professional/national meeting or conference. This funding opportunity was announced on April 3, 2015. The application deadline is June 29, 2015. For more information, please visit ACF's Full Funding Opportunity Announcement.

 

CDC: Asian Language Tobacco Quitline

Funding Opportunity Number: CDC-RFA-DP15-1503

Tobacco cessation telephonic counseling services are an evidence-based intervention for smoking cessation. However, such services are limited for Asian immigrants with limited English proficiency. Several subgroups of Asian Americans have smoking rates that are higher than the general population, including men who predominantly speak Chinese (including Cantonese and Mandarin), Korean, and Vietnamese languages. Traditional state quitline services have not adequately met the needs of callers who predominantly speak these languages. Providing culturally and linguistically appropriate promotion for an Asian quitline is highly specialized and can be challenging with limited expertise available. This funding opportunity was announced on April 29, 2015. The application deadline is June 29, 2015. For more information, please visit CDC's Full Funding Opportunity Announcement.

 

FDA: Development, Implementation, and Management of a Funding System to Advance Conformance with the Voluntary National Retail Food Regulatory Program Standards

Funding Opportunity Number: RFA-FD-15-037

The intended outcome of this Funding Opportunity Announcement (FOA) is the expansion of the existing program in which State, local, tribal, and territorial retail food regulatory programs can apply and be sub-awarded funds for completion of projects and training to enhance conformance with the Voluntary National Retail Food Regulatory Program Standards (VNRFRPS or Retail Program Standards). Funds will be awarded to a national association/organization to administer and award funds to State, local, territorial, and tribal jurisdictions to facilitate long-term improvements and advancement of the Retail Program Standards. This funding opportunity was announced on April 29, 2015. The application deadline is July 10, 2015. For more information, please visit FDA's Full Funding Opportunity Announcement.

 

FDA: Data Concepts and Terminology Standards for the Support of Human Drug Development and Evaluation

Funding Opportunity Number: RFA-FD-15-033

The Center for Drug Evaluation and Research (CDER) receives a vast and growing amount of data in a variety of regulatory submissions from a multitude of sources and in a variety of formats. This wealth of data holds great potential to advance CDER’s regulatory and scientific work, but the present lack of standardization creates significant challenges to realizing that potential. The volume and complexity of drug-related information submitted to CDER for regulatory review is creating significant challenges to the Center’s ability to efficiently and effectively perform its critical public health mission. The lack of standardized data affects CDER’s review processes by curtailing a reviewer’s ability to perform integral tasks such as rapid acquisition, analysis, storage and reporting of regulatory data. Improved data quality, accessibility and predictability will give reviewers more time to carry out complex analyses, ask in-depth questions and address late-emerging issues. Standardized data will allow reviewers to increase review consistency and perform evaluations across the drug lifecycle. This will enhance the Center’s performance across key drug regulatory functions and ongoing business operations, including pre-market review, post-market safety, oversight of drug quality, and oversight of drug promotion. This funding opportunity was announced on May 1, 2015. The application deadline is July 17, 2015. For more information, please visit FDA's Full Funding Opportunity Announcement.

 

FDA: Building towards Statistically-Based Pharmaceutical Quality Standards

Funding Opportunity Number: RFA-FD-15-031

The goal of this Funding Opportunity Announcement (FOA) is to generate data and develop a statistical sampling and analysis strategy to aid in drafting data-based guidance in support of the use of appropriate statistical tools and standards. Specifically, the development of standards for statistical methods suitable to drive industry towards increased product and process understanding throughout the lifecycle of a product. The project will provide data, sampling and data analysis approaches to inform for the agency and the human pharmaceutical industry to advance the development of risk- and science-based standards. These projects could be split into subsets by product type, process type, manufacturing complexity and/or therapeutic index to facilitate understanding. This funding opportunity was announced on April 29, 2015. The application deadline is July 7, 2015. For more information, please visit FDA's Full Funding Opportunity Announcement.

 

HRSA: Dissemination of Evidence-Informed Interventions to Improve Health Outcomes along the HIV Care Continuum – Dissemination and Evaluation Center

Funding Opportunity Number: HRSA-15-030

This Funding Opportunity Announcement (FOA) solicits applications to serve as a Dissemination and Evaluation Center (DEC) for a new Ryan White HIV/AIDS Program Special Projects of National Significance (SPNS) initiative entitled Dissemination of Evidence-Informed Interventions to Improve Health Outcomes along the HIV Care Continuum.  The goal of this FOA is to disseminate and evaluate the implementation of evidence-informed interventions adapted from previous SPNS initiatives in health care settings. The awardee will first be expected to adapt these interventions to better fit into the new health care environment, and then conduct a multi-site evaluation of their implementation at up to 12 performance sites interested in incorporating these interventions into their change management processes. The performance sites will be funded under a separate funding mechanism.  Evaluation results will inform best practices and lessons learned to be included in additional dissemination efforts.  In its first year of funding, the DEC will develop four implementation-ready interventions adapted from previous Special Projects of National Significance initiatives. The DEC will develop web-based materials for dissemination of  each intervention, listing its activity components; theoretical foundations; staffing and training requirements; costs (if available); and previously published evidence-informed research and evaluation reports and journal articles.  Each intervention will have its own webpage with these materials, to be published on the existing TARGET (Technical Assistance Resources, Guidance, Education and Training) Center website. Also during Year 1, the DEC will design a multi-site evaluation plan to assess the fidelity, effectiveness and costs of these interventions when implemented in Years 2 through 4 of the initiative. The DEC also will lead the development of implementation plans for the four interventions, working in close collaboration with an Implementation Technical Assistance Center (ITAC).  The DEC will also assist the ITAC in the development of technical assistance (TA) agendas informed by those implementation plans. This funding opportunity was announced on April 27, 2015. The application deadline is June 22, 2015. For more information, please visit HRSA's Full Funding Opportunity Announcement.

 

HRSA: Telehealth Focused Rural Health Research Center Cooperative Agreement

Funding Opportunity Number: HRSA-15-149

This Funding Opportunity Announcement (FOA) solicits applications for the Telehealth Focused Rural Health Research Center (RHRC) program.  The purpose of this program is to increase the amount of publicly available, high quality, impartial, clinically-informed and policy-relevant research related to telehealth. This research will assist rural health providers and decision-makers at the Federal, state and local levels by contributing to the policy-relevant evidence base of telehealth services. The awardee will provide information that includes, but is not limited to, the impact of telehealth services in rural and underserved communities on access to health care, population health, health care spending (both for payers and for the patients receiving the services), quality of care, home health, clinical delivery of care, and the comparative effectiveness of specific telehealth services relative to in-person services in the same clinical area. This funding opportunity was announced on April 29, 2015. The application deadline is June 29, 2015. For more information, please visit HRSA's Full Funding Opportunity Announcement.

 

DARPA: Restoring Active Memory Replay

Funding Opportunity Number: DARPA-BAA-15-34

The Defense Advanced Research Projects Agency (DARPA) Restoring Active Memory (RAM) Replay program is interested in investigating memory replay with respect to the consolidation of episodic memories and newly learned skills, and how these memories are recalled and utilized by humans during subsequent task performance. Respondents to this Broad Agency Announcement (BAA) must propose novel approaches to quantitatively model various parameters associated with human memory replay, and to utilize this model in the development of interventions that assess quality of replay and enable and improve associated memory recall during operationally relevant tasks. This funding opportunity was announced on April 27, 2015. The application deadline is June 16, 2015. For more information, please visit DARPA's Full Funding Opportunity Announcement.

 

DARPA: Biological Technologies

Funding Opportunity Number: DARPA-BAA-15-35

The Defense Advanced Research Projects Agency (DARPA) is soliciting innovative research proposals to investigate leading edge approaches that enable revolutionary advances in science, technologies, or systems at the intersection of biology with engineering and the physical and computer sciences. DARPA seeks unconventional approaches that are outside the mainstream, challenge assumptions, and have the potential to radically change established practice, lead to extraordinary outcomes, and create entirely new fields. DARPA’s overarching goal is to develop, demonstrate, and transition biological- based technologies as part of the toolkit available to DARPA stakeholders. DARPA encourages efforts that are creative and agile both in terms of the technologies proposed and in the structure of the approach. This funding opportunity was announced on April 29, 2015. The application deadline is April 28, 2016. For more information, please visit DARPA's Full Funding Opportunity Announcement.

 

USAMRAA: Multiple Sclerosis Pilot Clinical Trial Award

Funding Opportunity Number: W81XWH-15-MSRP-PCTA

The Pilot Clinical Trial Award (PCTA) supports early-phase, proof-of-principle clinical trials to investigate hypothesis-based, innovative interventions that have the potential to result in a profound impact on management of multiple sclerosis (MS) symptoms. While therapeutic approaches proposed for testing through the PCTA must represent novel, hypothesis-based, “outside-the-box” approaches for treating MS symptoms, they may include therapies already in clinical use, or undergoing clinical testing, for other diseases, provided that the proposed use for MS would lead to a major advancement for treating one of the disease symptoms. It is anticipated that outcomes from studies funded by this award will provide scientific rationale for subsequent development of larger, efficacy-based clinical trials of interventions that will transform MS patient care. The PCTA will support clinical trials encompassing Phase 0, Phase I, or pilot Phase II for drugs or drug combinations, Class II or III for devices, or other types of trials that conduct early clinical testing of innovative approaches for MS symptoms. Examples of acceptable studies include but are not limited to (1) identification of an appropriate population for the proposed study, (2) identification of the dosage, duration, and/or delivery strategy of an intervention, (3) evaluation of the feasibility of the intervention in MS, and (4) evaluation of efficacy and safety issues. This funding opportunity was announced on April 28, 2015. The application deadline is September 10, 2015. For more information, please visit the Army's Full Funding Opportunity Announcement.

 

USAMRAA: Multiple Sclerosis Investigator-Initiated Research Award

Funding Opportunity Number: W81XWH-15-MSRP-IIRA

The Multiple Sclerosis Investigator-Initiated Research Award supports highly rigorous, high-impact research projects that have the potential to make an important contribution to MS research and/or patient care. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to MS and the proposed research project. All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed. This funding opportunity was announced on April 28, 2015. The application deadline is September 10, 2015. For more information, please visit the Army's Full Funding Opportunity Announcement.

 

USAMRAA: Neuromusculoskeletal Injuries Award

Funding Opportunity Number: W81XWH-15-JPC-8-CRMRP-NMSIRA

The Neuromusculoskeletal Injuries Research Award (NMSIRA) is intended to support preclinical research and clinical trials on the reintegration after injury, functional utility of assistive devices related to the human-device interface, secondary health effects following severe extremity injury, and optimizing rehabilitation and device prescription for patients with neuromusculoskeletal injury. Applications must specifically address one or more of the following focus areas specified in the full Funding Opportunity Announcement (FOA), including (1) optimal restoration of physical and psychosocial reintegration following neuromusculoskeletal injury; (2) efficacious social support strategies; (3) limited innovative technologies for interconnectivity; (4) methods and technologies to assist and promote lifelong wellness and improved quality of life; (5) validated methods that assess and facilitate effective return to desired real-world functional performance. This funding opportunity was announced on April 28, 2015. The application deadline is August 17, 2015. For more information, please visit the Army's Full Funding Opportunity Announcement.

 

 

NIH Funding Opportunity Announcements:

 

NIH: Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment

Funding Opportunity Number: PA-15-188

Pain is a substantial public health issue. It is estimated that about 100 million Americans suffer from chronic pain.  Opioids have been increasingly used to treat chronic pain, and there has been an increase in the number of opioid prescriptions, which has caused a concomitant rise in prescription opioid abuse. Recently, there has been a resurgence in interest in the potential medical utility of cannabis and its constituents. Public perception is that cannabis has therapeutic benefit, especially in the treatment of pain, and there is some preliminary epidemiological and clinical research that supports possible benefits, yet to date there have not been adequate large controlled trials to support these claims. The purpose of this NIH Pain Consortium-endorsed Funding Opportunity Announcement (FOA) is to support projects examining the therapeutic potential of cannabinoids and the endocannabinoid system across a variety of pain conditions. Research supported under this FOA is wide-ranging. In general, the goal is to understand the role of cannabinoids in the management of chronic pain, in part to help mitigate the high rate of use and abuse of opioids.  This funding opportunity was announced on April 28, 2015. The application deadline is October 5, 2015. For more information, please visit NIH's Full Funding Opportunity Announcement.

 

NIH: Translational Research: Novel Interventions for Prevention and Treatment of Age-related Conditions

Funding Opportunity Number: PAR-15-190

This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research projects to accelerate the pace of development of novel therapeutics involving biologics, pharmacological and non-pharmacological approaches for preventing and treating key health issues affecting the elderly. For the purposes of this FOA, translational research on aging is defined as the application of basic and clinical biomedical findings towards the development of new strategies for prevention and treatment of age-related pathologies. This funding opportunity was announced on April 28, 2015. The application deadline is October 16, 2015. For more information, please visit NIH's Full Funding Opportunity Announcement.

 

NIH: Translational Research: Research Leading to New Health Care Practices, Community Programs and Policies Affecting Older Persons

Funding Opportunity Number: PAR-15-191

This funding opportunity announcement (FOA) encourages exploratory/developmental research projects on translational research directed towards development of health care practices, community programs and policies, including monitoring and quality improvement for pharmacological and non-pharmacological approaches for preventing and treating key health issues affecting the elderly. For the purposes of this FOA, translational research on aging is defined as research to gather information needed to develop or evaluate methods of translating results from clinical studies into everyday clinical practice and health decision making (e.g., adapting an efficacious intervention for application in clinical practice and evaluating its effectiveness in different clinical settings). Methods for translational research include but are not limited to intervention studies, systematic reviews, meta-analysis, outcomes research and implementation research. This funding opportunity was announced on April 28, 2015. The application deadline is October 16, 2015. For more information, please visit NIH's Full Funding Opportunity Announcement.

 

NIH: Analyses of Human Datasets and Biospecimens to Characterize Aging-related Phenotypes Relationships to Circulating Polypeptides and Proteins that Reverse or Accelerate Aging Changes

Funding Opportunity Number: RFA-AG-16-012

This Funding Opportunity Announcement (FOA) invites applications to analyze existing datasets and stored biospecimens from human cohorts (e.g., epidemiologic studies, clinical trials) to advance understanding of potential effects in humans of polypeptides and proteins whose circulating levels change with age, and for which experimental evidence indicates reversal or acceleration of aging changes. Proposed studies in response to this FOA should address potential relationships of any selected polypeptide or protein to multiple outcomes, in order to evaluate both potential beneficial and adverse effects. This funding opportunity was announced on April 28, 2015. A letter of intent is due by June 9, 2015. The application deadline is July 9, 2015. For more information, please visit NIH's Full Funding Opportunity Announcement.

 

NIH: Immune System Plasticity in the Pathogenesis and Treatment of Complex Dental, Oral, and Craniofacial Diseases

Funding Opportunity Number: PAR-15-192

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research projects to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial diseases. The goal of this FOA is to advance knowledge of the immunological basis of dental, oral, and craniofacial diseases, and to develop tools and technologies for precise modulation of the immune system to restore or maintain health. The expectation is that new knowledge derived from this research will facilitate development of novel immunomodulatory therapies to prevent disease onset or reverse disease progression. This funding opportunity was announced on April 28, 2015. The application deadline is October 5, 2015. For more information, please visit NIH's Full Funding Opportunity Announcement.

 

NIH: Lasker Clinical Research Scholars Program

Funding Opportunity Number: PAR-15-189

This Funding Opportunity Announcement (FOA) solicits applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases.  In the first phase, Lasker scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets.  In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility, or can be considered to remain as an investigator within the intramural program. This funding opportunity was announced on April 28, 2015. The application deadline is August 27, 2015. For more information, please visit NIH's Full Funding Opportunity Announcement.

 

NIH: Immune System Plasticity in the Pathogenesis and Treatment of Complex Dental, Oral, and Craniofacial Diseases

Funding Opportunity Number: PAR-15-193

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research projects to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial diseases. The goal is to advance knowledge of the immunological basis of dental, oral, and craniofacial diseases, and to develop tools and technologies for precise modulation of the immune system to restore or maintain health. The expectation is that new knowledge derived from this research will facilitate development of novel immunomodulatory therapies to prevent disease onset or reverse disease progression. This funding opportunity was announced on April 28, 2015. The application deadline is October 16, 2015. For more information, please visit NIH's Full Funding Opportunity Announcement.

 

NIH: Consortia for Innovative AIDS Research in Nonhuman Primates

Funding Opportunity Number: RFA-AI-15-022

This Funding Opportunity Announcement (FOA) solicits applications that will study a vaccine shown to have protected at least a subset of Nonhuman Primates (NHP) from lethal Simian Immunodeficiency Virus (SIV) or Simian-Human Immunodeficiency Virus (SHIV) mucosal challenge. The goals of this program include (1) establishment of a collaborative multidisciplinary research NHP Consortium that will primarily focus on elucidating the mechanism(s) whereby this protective vaccine has blocked initial infection or has prevented establishment of persistent systemic infection and (2) research focused on innovative approaches that include a vaccine (and/or other immune interventions) as part of strategies to eliminate SIV/SHIV proviral reservoirs or lead to sustained remission after discontinuation of highly active antiretroviral therapy (HAART) in NHP. This funding opportunity was announced on April 29, 2015. A letter of intent is due by June 29, 2015. The application deadline is July 29, 2015. For more information, please visit NIH's Full Funding Opportunity Announcement.

 

NIH: NeuroNEXT Infrastructure Resource Access

Funding Opportunity Number: PAR-15-195

This Funding Opportunity Announcement (FOA) encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may provide the data required for designing a future trial for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the National Institute of Neurological Diseases and Stroke’s (NINDS') strategic plan and clinical research interests. Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. This funding opportunity was announced on April 30, 2015. Applications will be accepted on a rolling basis and evaluated in rounds three times per year. The end of the next round is  July 12, 2015. For more information, please visit NIH's Full Funding Opportunity Announcement.

 

NIH: Developmental AIDS Research Center on Mental Health and HIV/AIDs

Funding Opportunity Number: PAR-15-196 and PAR-15-197

This Funding Opportunity Announcement (FOA) solicits applications for Center Core grants to support Developmental AIDS Research Centers (D-ARC). The D-ARC program is intended to provide infrastructural support that facilitates the development of high impact science in HIV/AIDS and mental health that is relevant to the NIMH mission. This FOA intends to support innovative, interdisciplinary research in several areas including basic, neurological, behavioral and social, integrated biobehavioral, applied, clinical, translational, and implementation science. These funding opportunities were announced on May 1, 2015. The initial application deadline is September 14, 2015. A letter of intent is due 30 days prior to the associated application deadline. For more information, please visit NIH's Full Funding Opportunity Announcements for PAR-15-196 and PAR-15-197.


Association Management Software Powered by YourMembership  ::  Legal